AVEO Pharmaceuticals to Present at First Annual Boston Biotech R&D Conference
CAMBRIDGE, MA [October 20, 2008] – AVEO Pharmaceuticals today announced that Murray O. Robinson, Ph.D., senior vice president of oncology, will present at the 2008 Boston Biotech R&D Conference on Wednesday, October 22, 2008, 2:20 p.m. (ET) at Harvard Medical School. This conference will bring luminaries from top academic institutions that have been instrumental in establishing the strong Boston biotech community together with executives from several of the area’s most promising emerging biopharmaceutical companies and leaders from the venture capital community and equity markets.
Dr. Robinson will lead a session entitled, Addressing the Challenges of Successful Oncology Drug Development: Matching Molecularly Targeted Drugs to Responsive Patient Populations, moderated by Edward Tenthoff of Piper Jaffray. During the presentation, Dr. Robinson will discuss AVEO’s proprietary tumor models, and how the insights obtained through this unique cancer biology platform enable AVEO to increase the probability of clinical success of its cancer drug development programs. He will also highlight recent progress with the company’s lead product candidate, AV-951, AVEO’s highly potent and selective triple-VEGFR inhibitor in Phase 2 clinical development.
“We are very pleased to be participating in the first ever Boston Biotech R&D Conference,” said Dr. Robinson. “I look forward to discussing AVEO and our innovative approach to cancer drug development.”
About the Boston Biotech R&D Conference
The 2008 Boston Biotech R&D Conference will take place at Harvard Medical School and will highlight the work of top academics as well as up-and-coming biotech companies in the Boston-area. The agenda features keynote speeches from several luminaries in medicine and research, including Jeffrey S. Flier, Dean of Harvard Medical School, Leonard Guarente, Ronald Kahn, Eric S. Lander, Robert Langer, Phillip Sharp, David Sinclair, as well as CEOs of the next generation of leading biotech and pharma companies from the Boston area. The conference is sponsored by Alexandria Real Estate Equities Inc., Pure Communications Inc., and Rodman & Renshaw, LLC. For more information, visit http://www.bostonbiotechconference.com/.
AVEO is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company's website at http://www.aveopharma.com/.